Rule 4.2A

Appendix 4EPreliminary Final Report

1. Company details

Name of entity

Pro Medicus Limited

ABN or equivalent company reference Financial year ended ('current period')

Financial year ended ('previous period')

25 006 194 752

30 June 2018

30 June 2017

2. Results for announcement to the market

ASX Listing Rules Ref		2018 A\$'000	2017 A\$'000	% change
2.1	Revenue from continuing operations	36,017	31,619	13.9%
2.2	Underlying Profit after Tax (minus currency gains/(losses)	12,567	9,865	27.4%
	Currency gains/(losses) after tax (including costs of currency instruments)	177	(544)	N/A
	Profit/(Loss) from ordinary activities after tax attributable to members	12,744	9,321	36.7%
2.3	Net Profit/(Loss) for the period attributable to members	12,744		
	% change up/(down) of Net Profit/(Loss) for the period attributable to members from the previous corresponding period.	Up 36.7%		

2.4	Dividends (distributions)	Amount per security	Franked/Unfranked amount per security	
	Dividend amount per security			
	Final Dividend (franked)	3.5 cents	3.5 cents	
	Interim dividend (franked)	2.5 cents	2.5 cents	
2.5	Record date for Final dividends	7 Septer	7 September 2018	
	Payment date for Final dividends	r Final dividends 27 September 2018		

2.6 Australia

The Group's Australian employees undertake research and development of Pro Medicus products (RIS) as well as sales and service/support functions.

The Group's Australian revenue was in line with the previous year (down 2.0%). The rollout of the Healthcare Imaging (Primary) contract announced in March 2017 commenced during the period. In May 2018, the company announced a major extension of its contract with I-MED, Australia's largest radiology provider. Once fully implemented the extension to the contract is estimated to provide an additional \$1.3m in revenue per annum.

Promedicus.net, the company's e-health offering, continued to hold its market position despite increasing competition.

North America

The North American team fulfil sales, marketing and professional services roles. Revenue from North America increased by 18.4% compared to the previous year. This was attributable to new sales to Yale New Haven Health and the sale of Visage Open Archive to Mercy Health, as well as an increase in transaction based revenue from sales of Visage technology as more contracts came on stream.

Europe

The Group's employees in its Berlin office undertake research and development of Visage Imaging products worldwide as well as sales, marketing and service/support functions for the Group's European operations. Revenue from our European operations increased by 33.2% from the previous year.

Financials

Reported profit after tax for the period was \$12.74m an increase of 36.7% from the previous year.

Full year revenue of the Group increased from \$31.62m to \$36.02m, an increase of 13.9%. As the Group's costs are relatively fixed, an increase in sales has a significant impact on profitability.

The key drivers of the profit increase were the significant increase in the performance of the North American and European operations, as well as unrealised foreign currency gains.

Underlying profit, which excludes currency movements was \$12.57m an increase of 27.4% from the previous year.

Shareholder Returns

The directors are confident that the holdings of reserve cash are sufficient to underpin the development and expansion needs of the company as the business looks to increase its penetration of existing markets.

3. Statement of Comprehensive Income

Please refer to the Statement of Comprehensive Income in the attached Financial Statements.

4. Statement of Financial Position

Please refer to the Statement of Financial Position in the attached Financial Statements.

5. Statement of cash flows

Please refer to the Statement of cash flows in the attached Financial Statements.

6.	Details of Dividends			
		2018 \$'000	2017 \$'000	
	Final Dividend	V 000	Ψ 000	
	A franked Final Dividend of 3.5 cents (2017: 2.5 cents) per share will be paid on 28 September 2017.	3,618	2,567	
	Current Year Interim			
	A franked Interim Dividend of 2.5 cents (2017: 1.5 cents unfranked) per share was paid on 23 March 2018.	2,584	1,540	
	No foreign sourced dividend or distribution is included in either the interim or final dividends.			
7.	7. Dividend or Distribution reinvestment plans			
	There are no dividend or distribution reinvestment plans in open	ration.		
8.	Statement of Retained Earnings			
	Please refer to Statement of Changes in Equity in the attached	Financial State	ements.	
9.	Net Tangible Assets per security 20	118	2017	
	Net Tangible Assets per security \$0	.30	\$0.23	
10.	Details of entities over which control has been gained or lost during the period			
	There are no entities over which control has been gained or lost during the period			
11.	Associates and joint venture entities			
	There are no associates or joint venture entities			
12.	Other significant information needed by an investor to make an information assessment of the entity's financial performance and financial position			
	Please refer to section 2.6			
13.	Foreign Entity accounting standards			
	Australian Accounting Standards & International Financial Repo	orting Standard	S	

14.	Commentary on results for the period.			
	The earnings per security and the nature of any dilution aspects.			
	Please refer to Note 7 of the attached Financial Statements.			
	Returns to shareholders including distributions and buy backs.			
	Please refer to Note 8 of the attached Financial Statements.			
	Significant features of operating performance. Please refer to section 2.6			
	Tribute for the decition 2.5.			
	The results of segments that are significant to an understanding of the business. Please refer to Note 5 of the attached Financial Statements.			
	r lease refer to Note 3 of the attached r mancial Statements.			
	Discussion of trends in performance.			
	Please refer to section 2.6.			
15.	Audit Statement			
	This report is becard an accounts to which one of the following applies			
	This report is based on accounts to which one of the following applies.			
	(Tick one) ☑ The ⁺accounts have been ☐ The ⁺accounts have been subject to			
	☐ The faccounts have been ☐ The faccounts have been subject to audited.			
	☐ The +accounts are in the ☐ The +accounts have <i>not</i> yet been			
	process of being audited. audited or reviewed.			

Sign here: Date: 16 August 2018

Print name: Sam Hupert

Chief Executive Officer